ADMA Biologics (NASDAQ:ADMA) Posts Quarterly Earnings Results, Meets Expectations

ADMA Biologics (NASDAQ:ADMA) issued its earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16, Zacks reports. The firm had revenue of $134.22 million for the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.15 earnings per share. ADMA Biologics updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

ADMA Biologics Stock Up 3.5%

Shares of NASDAQ ADMA traded up $0.49 on Friday, hitting $14.52. The company had a trading volume of 4,568,297 shares, compared to its average volume of 3,228,790. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics has a 12-month low of $13.50 and a 12-month high of $25.67. The firm has a market capitalization of $3.46 billion, a P/E ratio of 16.88 and a beta of 0.40. The business has a 50 day moving average of $15.43 and a two-hundred day moving average of $17.92.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus target price of $27.67.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its stake in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 700 shares during the period. Cerity Partners LLC boosted its stake in shares of ADMA Biologics by 1.8% in the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after purchasing an additional 869 shares during the period. EverSource Wealth Advisors LLC grew its holdings in ADMA Biologics by 385.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares in the last quarter. HUB Investment Partners LLC increased its stake in ADMA Biologics by 18.5% during the 2nd quarter. HUB Investment Partners LLC now owns 18,560 shares of the biotechnology company’s stock worth $338,000 after buying an additional 2,892 shares during the period. Finally, Vident Advisory LLC increased its stake in ADMA Biologics by 3.5% during the 2nd quarter. Vident Advisory LLC now owns 142,749 shares of the biotechnology company’s stock worth $2,599,000 after buying an additional 4,874 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.